soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Semaglutide cardiovascular outcomes align more

When we eat these comfort foods, our brain releases dopamine, creating a powerful, addictive cycle

Semaglutide is a GLP-1 receptor agonist that has been approved by the FDA for weight management and the treatment of type 2 diabetes

Still, some organizations worry that the FDAs plans to restrict the active ingredients in compounded GLP-1 drugs could affect the compounding industry at large

Conversely, eating a heavy or fatty meal immediately before injection can intensify nausea in some patients, though this varies widely based on individual sensitivity

Improved Insulin Sensitivity Improved Insulin Sensitivity As estrogen levels decline during perimenopause, insulin resistance often increases , making it easier to gain weight and harder to lose it